Abstract
In this chapter we review the current state of the art for uveal melanoma. Diagnosis, prognosis, and disease management are reviewed with special attention to the latest developments in molecular genetics. We also review the many eye conserving options for treatment of this disease with a special focus on advanced episcleral plaque brachytherapy. Modern therapeutic advances have now reached a point that nearly all eyes can be managed in a conservative manner with significant visual preservation for most patients.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Singh AD, Bergman L, Seregard S. Uveal melanoma: epidemiologic aspects. Ophthalmol Clin N Am. 2005;18(1):75–84. viii
Egan KM, Seddon JM, Glynn RJ, et al. Epidemiologic aspects of uveal melanoma. Surv Ophthalmol. 1988;32(4):239–51.
Weis E, Salopek TG, McKinnon JG, et al. Management of uveal melanoma: a consensus-based provincial clinical practice guideline. Curr Oncol. 2016;23(1):e57–64.
Gallagher RP, Elwood JM, Rootman J, et al. Risk factors for ocular melanoma: Western Canada Melanoma Study. J Natl Cancer Inst. 1985;74(4):775–8.
Zloto O, Pe'er J, Frenkel S. Gender differences in clinical presentation and prognosis of uveal melanoma. Invest Ophthalmol Vis Sci. 2013;54(1):652–6.
Weis E, Shah CP, Lajous M, et al. The association of cutaneous and iris nevi with uveal melanoma: a meta-analysis. Ophthalmology. 2009;116(3):536–43.e2.
Singh AD, Kalyani P, Topham A. Estimating the risk of malignant transformation of a choroidal nevus. Ophthalmology. 2005;112(10):1784–9.
Yanoff M, Zimmerman LE. Histogenesis of malignant melanomas of the uvea. II. Relationship of uveal nevi to malignant melanomas. Cancer. 1967;20(4):493–507.
Guenel P, Laforest L, Cyr D, et al. Occupational risk factors, ultraviolet radiation, and ocular melanoma: a case-control study in France. Cancer Causes Control. 2001;12(5):451–9.
Holly EA, Aston DA, Char DH, et al. Uveal melanoma in relation to ultraviolet light exposure and host factors. Cancer Res. 1990;50(18):5773–7.
Seddon JM, Gragoudas ES, Glynn RJ, et al. Host factors, UV radiation, and risk of uveal melanoma. A case-control study. Arch Ophthalmol. 1990;108(9):1274–80.
Lynch HT, Anderson DE, Krush AJ. Heredity and intraocular malignant melanoma. Study of two families and review of forty-five cases. Cancer. 1968;21(1):119–25.
Lynch HT, Krush AJ. Heredity and malignant melanoma: implications for early cancer detection. Can Med Assoc J. 1968;99(1):17–21.
Walker JP, Weiter JJ, Albert DM, et al. Uveal malignant melanoma in three generations of the same family. Am J Ophthalmol. 1979;88(4):723–6.
Greene MH, Sanders RJ, Chu FC, et al. The familial occurrence of cutaneous melanoma, intraocular melanoma, and the dysplastic nevus syndrome. Am J Ophthalmol. 1983;96(2):238–45.
Vink J, Crijns MB, Mooy CM, et al. Ocular melanoma in families with dysplastic nevus syndrome. J Am Acad Dermatol. 1990;23(5 Pt 1):858–62.
Singh AD, Wang MX, Donoso LA, et al. Genetic aspects of uveal melanoma: a brief review. Semin Oncol. 1996;23(6):768–72.
Bacin F, Kemeny JL, D’Hermies F, et al. Malignant melanoma of the choroid associated with neurofibromatosis. J Fr Ophtalmol. 1993;16(3):184–90.
Wiznia RA, Freedman JK, Mancini AD, et al. Malignant melanoma of the choroid in neurofibromatosis. Am J Ophthalmol. 1978;86(5):684–7.
Yanoff M, Zimmerman LE. Histogenesis of malignant melanomas of the uvea. 3. The relationship of congenital ocular melanocytosis and neurofibromatosis in uveal melanomas. Arch Ophthalmol. 1967;77(3):331–6.
Rai K, Pilarski R, Boru G, et al. Germline BAP1 alterations in familial uveal melanoma. Genes Chromosomes Cancer. 2017;56(2):168–74.
Decatur CL, Ong E, Garg N, et al. Driver mutations in uveal melanoma: associations with gene expression profile and patient outcomes. JAMA Ophthalmol. 2016;134(7):728–33.
Velazquez N, Jones IS. Ocular and oculodermal melanocytosis associated with uveal melanoma. Ophthalmology. 1983;90(12):1472–6.
Carreno E, Saornil MA, Garcia-Alvarez C, et al. Prevalence of ocular and oculodermal melanocytosis in Spanish population with uveal melanoma. Eye (Lond). 2012;26(1):159–62.
Shields CL, Kaliki S, Livesey M, et al. Association of ocular and oculodermal melanocytosis with the rate of uveal melanoma metastasis: analysis of 7872 consecutive eyes. JAMA Ophthalmol. 2013;131(8):993–1003.
Shields CL, Furuta M, Berman EL, et al. Choroidal nevus transformation into melanoma: analysis of 2514 consecutive cases. Arch Ophthalmol. 2009;127(8):981–7.
Kivela T. Diagnosis of uveal melanoma. Dev Ophthalmol. 2012;49:1–15.
Tarlan B, Kiratli H. Uveal melanoma: current trends in diagnosis and management. Turk J Ophthalmol. 2016;46(3):123–37.
Factors predictive of growth and treatment of small choroidal melanoma: COMS report no. 5. The Collaborative Ocular Melanoma Study Group. Arch Ophthalmol. 1997;115(12):1537–1544.
Accuracy of diagnosis of choroidal melanomas in the Collaborative Ocular Melanoma Study. COMS report no. 1. Arch Ophthalmol. 1990;108(9):1268–1273.
Margo CE. The accuracy of diagnosis of posterior uveal melanoma. Arch Ophthalmol. 1997;115(3):432–4.
Kielar RA. Choroidal melanoma appearing as vitreous hemorrhage. Ann Ophthalmol. 1982;14(5):461–4.
Skalka HW. Choroidal hemorrhage simulating malignant melanoma. J Clin Ultrasound. 1982;10(4):190–2.
Fraser DJ Jr, Font RL. Ocular inflammation and hemorrhage as initial manifestations of uveal malignant melanoma. Incidence and prognosis. Arch Ophthalmol. 1979;97(7):1311–4.
Giuliari GP, Connor A, Simpson ER. Amelanotic choroidal melanoma. Lancet. 2011;377(9768):848.
Lee DS, Anderson SF, Perez EM, et al. Amelanotic choroidal nevus and melanoma: cytology, tumor size, and pigmentation as prognostic indicators. Optom Vis Sci. 2001;78(7):483–91.
Gibran SK, Kapoor KG. Management of exudative retinal detachment in choroidal melanoma. Clin Exp Ophthalmol. 2009;37(7):654–9.
Harbour JW, Ahmad S, El-Bash M. Rate of resolution of exudative retinal detachment after plaque radiotherapy for uveal melanoma. Arch Ophthalmol. 2002;120(11):1463–9.
Kivela T, Eskelin S, Makitie T, et al. Exudative retinal detachment from malignant uveal melanoma: predictors and prognostic significance. Invest Ophthalmol Vis Sci. 2001;42(9):2085–93.
Collaborative Ocular Melanoma Study G, Boldt HC, Byrne SF, et al. Baseline echographic characteristics of tumors in eyes of patients enrolled in the Collaborative Ocular Melanoma Study: COMS report no. 29. Ophthalmology. 2008;115(8):1390–7. 7.e1–2
Collaborative Ocular Melanoma Study G. Comparison of clinical, echographic, and histopathological measurements from eyes with medium-sized choroidal melanoma in the collaborative ocular melanoma study: COMS report no. 21. Arch Ophthalmol. 2003;121(8):1163–71.
Margo CE. The collaborative ocular melanoma study: an overview. Cancer Control. 2004;11(5):304–9.
Amin MB, Edge SB, Cancer. AJCo. AJCC cancer staging manual 2017. 2017.
Augsburger JJ, Correa ZM, Schneider S, et al. Diagnostic transvitreal fine-needle aspiration biopsy of small melanocytic choroidal tumors in nevus versus melanoma category. Trans Am Ophthalmol Soc. 2002;100:225–32. discussion 32–4
Singh AD, Medina CA, Singh N, et al. Fine-needle aspiration biopsy of uveal melanoma: outcomes and complications. Br J Ophthalmol. 2016;100(4):456–62.
De Croock L, Verbraeken H. Metastatic uveal melanoma: diagnosis and treatment. A literature review. Bull Soc Belge Ophtalmol. 2002;286:59–63.
Kim IK, Lane AM, Gragoudas ES. Survival in patients with presymptomatic diagnosis of metastatic uveal melanoma. Arch Ophthalmol. 2010;128(7):871–5.
Diener-West M, Reynolds SM, Agugliaro DJ, et al. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. Arch Ophthalmol. 2005;123(12):1639–43.
Shields JA, Augsburger JJ, Brown GC, et al. The differential diagnosis of posterior uveal melanoma. Ophthalmology. 1980;87(6):518–22.
Histopathologic characteristics of uveal melanomas in eyes enucleated from the Collaborative Ocular Melanoma Study. COMS report no. 6. Am J Ophthalmol. 1998;125(6):745–766.
Coleman K, Baak JP, van Diest PJ, et al. Prognostic value of morphometric features and the Callender classification in uveal melanomas. Ophthalmology. 1996;103(10):1634–41.
Collaborative Ocular Melanoma Study G. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15. Arch Ophthalmol. 2001;119(5):670–6.
McLean IW, Ainbinder DJ, Gamel JW, et al. Choroidal-ciliary body melanoma. A multivariate survival analysis of tumor location. Ophthalmology. 1995;102(7):1060–4.
Damato BE, Heimann H, Kalirai H, et al. Age, survival predictors, and metastatic death in patients with choroidal melanoma: tentative evidence of a therapeutic effect on survival. JAMA Ophthalmol. 2014;132(5):605–13.
Collaborative Ocular Melanoma Study G. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report no. 28. Arch Ophthalmol. 2006;124(12):1684–93.
Mortality in patients with small choroidal melanoma. COMS report no. 4. The collaborative ocular melanoma study group. Arch Ophthalmol. 1997;115(7):886–893.
The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma II: initial mortality findings. COMS report no. 10. Am J Ophthalmol. 1998;125(6):779–796.
Correa ZM. Assessing prognosis in uveal melanoma. Cancer Control. 2016;23(2):93–8.
Onken MD, Worley LA, Char DH, et al. Collaborative Ocular Oncology Group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma. Ophthalmology. 2012;119(8):1596–603.
Dopierala J, Damato BE, Lake SL, et al. Genetic heterogeneity in uveal melanoma assessed by multiplex ligation-dependent probe amplification. Invest Ophthalmol Vis Sci. 2010;51(10):4898–905.
Singh AD, Donoso LA. Genetic aspects of uveal melanoma. Int Ophthalmol Clin. 1993;33(3):47–52.
Singh AD, Boghosian-Sell L, Wary KK, et al. Cytogenetic findings in primary uveal melanoma. Cancer Genet Cytogenet. 1994;72(2):109–15.
Singh AD. Prognostication of uveal melanoma: a work in progress. JAMA Ophthalmol. 2016;134(7):740–1.
Kilic E, van Gils W, Lodder E, et al. Clinical and cytogenetic analyses in uveal melanoma. Invest Ophthalmol Vis Sci. 2006;47(9):3703–7.
Field MG, Harbour JW. Recent developments in prognostic and predictive testing in uveal melanoma. Curr Opin Ophthalmol. 2014;25(3):234–9.
Harbour JW. A prognostic test to predict the risk of metastasis in uveal melanoma based on a 15-gene expression profile. Methods Mol Biol. 2014;1102:427–40.
Jampol LM, Moy CS, Murray TG, et al. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: IV. Local treatment failure and enucleation in the first 5 years after brachytherapy. COMS report no. 19. Ophthalmology. 2002;109(12):2197–206.
Marucci L, Ancukiewicz M, Lane AM, et al. Uveal melanoma recurrence after fractionated proton beam therapy: comparison of survival in patients treated with reirradiation or with enucleation. Int J Radiat Oncol Biol Phys. 2011;79(3):842–6.
Ophthalmic Oncology Task F. Local recurrence significantly increases the risk of metastatic uveal melanoma. Ophthalmology. 2016;123(1):86–91.
Foulds WS, Damato BE, Burton RL. Local resection versus enucleation in the management of choroidal melanoma. Eye. 1987;1(Pt 6):676–9.
Damato B, Foulds WS. Indications for trans-scleral local resection of uveal melanoma. Br J Ophthalmol. 1996;80(11):1029–30.
Damato BE, Paul J, Foulds WS. Risk factors for residual and recurrent uveal melanoma after trans-scleral local resection. Br J Ophthalmol. 1996;80(2):102–8.
Damato BE. Local resection of uveal melanoma. Dev Ophthalmol. 2012;49:66–80.
Oosterhuis JA, Journee-de Korver HG, Kakebeeke-Kemme HM, et al. Transpupillary thermotherapy in choroidal melanomas. Arch Ophthalmol. 1995;113(3):315–21.
Journee-de Korver JG, Oosterhuis JA, Kakebeeke-Kemme HM, et al. Transpupillary thermotherapy (TTT) by infrared irradiation of choroidal melanoma. Doc Ophthalmol. 1992;82(3):185–91.
Journee-de Korver JG, Oosterhuis JA, de Wolff-Rouendaal D, et al. Histopathological findings in human choroidal melanomas after transpupillary thermotherapy. Br J Ophthalmol. 1997;81(3):234–9.
Shields CL, Shields JA, DePotter P, et al. Transpupillary thermotherapy in the management of choroidal melanoma. Ophthalmology. 1996;103(10):1642–50.
Shields CL, Shields JA, Cater J, et al. Transpupillary thermotherapy for choroidal melanoma: tumor control and visual results in 100 consecutive cases. Ophthalmology. 1998;105(4):581–90.
Kashani AH, Aaberg TM Jr, Capone A Jr. Vitreomacular traction as a consequence of posterior hyaloidal contraction after transpupillary thermotherapy. Am J Ophthalmol. 2013;155(5):937–45.
Shields CL, Shields JA. Transpupillary thermotherapy for choroidal melanoma. Curr Opin Ophthalmol. 1999;10(3):197–203.
Aaberg TM Jr, Bergstrom CS, Hickner ZJ, et al. Long-term results of primary transpupillary thermal therapy for the treatment of choroidal malignant melanoma. Br J Ophthalmol. 2008;92(6):741–6.
Win PH, Robertson DM, Buettner H, et al. Extended follow-up of small melanocytic choroidal tumors treated with transpupillary thermotherapy. Arch Ophthalmol. 2006;124(4):503–6.
Shields CL, Cater J, Shields JA, et al. Combined plaque radiotherapy and transpupillary thermotherapy for choroidal melanoma: tumor control and treatment complications in 270 consecutive patients. Arch Ophthalmol. 2002;120(7):933–40.
Bartlema YM, Oosterhuis JA, Journee-De Korver JG, et al. Combined plaque radiotherapy and transpupillary thermotherapy in choroidal melanoma: 5 years’ experience. Br J Ophthalmol. 2003;87(11):1370–3.
Oosterhuis JA, Journee-de Korver HG, Keunen JE. Transpupillary thermotherapy: results in 50 patients with choroidal melanoma. Arch Ophthalmol. 1998;116(2):157–62.
De Potter P, Jamart J. Adjuvant indocyanine green in transpupillary thermotherapy for choroidal melanoma. Ophthalmology. 2003;110(2):406–13. discussion 13–4
Stallard HB. Malignant melanoma of the choroid treated with radioactive applicators: Hunterian lecture delivered at the Royal College of Surgeons of England on 29th November 1960. Ann R Coll Surg Engl. 1961;29:170–82.
Augsburger JJ, Gamel JW, Lauritzen K, et al. Cobalt-60 plaque radiotherapy vs enucleation for posterior uveal melanoma. Am J Ophthalmol. 1990;109:585–92.
Earle J, Kline RW, Robertson DM. Selection of iodine 125 for the Collaborative Ocular Melanoma Study. Arch Ophthalmol. 1987;105:763–4.
Brualla L, Zaragoza FJ, Sauerwein W. Monte Carlo simulation of the treatment of eye tumors with (106)Ru plaques: a study on maximum tumor height and eccentric placement. Ocul Oncol Pathol. 2014;1:2–12.
Hawkins BS. Collaborative ocular melanoma study randomized trial of I-125 brachytherapy. Clin Trials. 2011;8:661–73.
Krohn J, Monge OR, Skorpen TN, et al. Posterior uveal melanoma treated with I-125 brachytherapy or primary enucleation. Eye. 2008;22:1398–403.
Shields CL, Naseripour M, Cater J, et al. Plaque radiotherapy for large posterior uveal melanomas (≥8-mm thick) in 354 consecutive patients 1. Ophthalmology. 2002;109:1838–49.
Rouberol F, Roy P, Kodjikian L, et al. Survival, anatomic, and functional long-term results in choroidal and ciliary body melanoma after ruthenium brachytherapy (15 years’ experience with beta-rays). Am J Ophthalmol. 2004;137:893–900.
Anteby II, Pe’er J. Need for confirmation of positioning of ruthenium plaques by postoperative B-scan ultrasonography. Ophthalmic Surg Lasers. 1996;27(12):1024–9.
Aziz HA, Al Zahrani YA, Bena J, et al. Episcleral brachytherapy of uveal melanoma: role of intraoperative echographic confirmation. Br J Ophthalmol. 2017;101(6):747–51.
Chang MY, Kamrava M, Demanes DJ, et al. Intraoperative ultrasonography-guided positioning of iodine 125 plaque brachytherapy in the treatment of choroidal melanoma. Ophthalmology. 2012;119(5):1073–7.
Tabandeh H, Chaudhry NA, Murray TG, et al. Intraoperative echographic localization of iodine-125 episcleral plaque for brachytherapy of choroidal melanoma. Am J Ophthalmol. 2000;129(2):199–204.
Design and methods of a clinical trial for a rare condition: The collaborative ocular melanoma study. Control Clin Trials. 1993;14:362–391.
Perez BA, Mettu P, Vajzovic L, et al. Uveal melanoma treated with iodine-125 episcleral plaque: an analysis of dose on disease control and visual outcomes. Int J Radiat Oncol Biol Phys. 2014;89:127–36.
Nath R, Anderson LL, Luxton G, et al. Dosimetry of interstitial brachytherapy sources: recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. Med Phys. 1995;22:209–34.
Wang Z, Nabhan M, Schild SE, et al. Charged particle radiation therapy for uveal melanoma: a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys. 2013;86:18–26.
Dieckmann K, Georg D, Zehetmayer M, et al. LINAC based stereotactic radiotherapy of uveal melanoma: 4 years clinical experience. Radiother Oncol. 2003;67:199–206.
Langmann G, Pendl G, Klaus-Müllner, et al. Gamma knife radiosurgery for uveal melanomas: an 8-year experience. J Neurosurg. 2000;93:184–8.
Gragoudas ES, Lane AM, Regan S, et al. A randomized controlled trial of varying radiation doses in the treatment of choroidal melanoma. Arch Ophthalmol. 2000;118:773–8.
Langmann G, Pendl G, Müllner K, et al. High-compared with low-dose radiosurgery for uveal melanomas. J Neurosurg. 2002;97:640–3.
Astrahan MA, Luxton G, Pu Q, et al. Conformal episcleral plaque therapy. Int J Radiat Oncol Biol Phys. 1997;39:505–19.
American Brachytherapy Society – Ophthalmic Oncology Task Force. Electronic address pec, Committee AO. The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma. Brachytherapy. 2014;13(1):1–14.
Verma V, Mehta MP. Clinical outcomes of proton radiotherapy for uveal melanoma. Clin Oncol. 2016;28:e17–27.
Mishra KK, Quivey JM, Daftari IK, et al. Long-term results of the UCSF-LBNL randomized trial: charged particle with helium ion versus iodine-125 plaque therapy for choroidal and ciliary body melanoma. Int J Radiat Oncol Biol Phys. 2015;92:376–83.
Char DH, Quivey JM, Castro JR, et al. Helium ions versus iodine 125 brachytherapy in the management of uveal melanoma. Ophthalmology. 1993;100:1547–54.
Berry JL, Dandapani SV, Stevanovic M, et al. Outcomes of choroidal melanomas treated with eye physics: a 20-year review. JAMA Ophthalmol. 2013;131:1435–42.
Bogner J, Petersch B, Georg D, et al. A noninvasive eye fixation and computer-aided eye monitoring system for linear accelerator-based stereotactic radiotherapy of uveal melanoma. Int J Radiat Oncol Biol Phys. 2003;56:1128–36.
Furdova A, Strmen P, Waczulikova I, et al. One-day session LINAC-based stereotactic radiosurgery of posterior uveal melanoma. Eur J Ophthalmol. 2011;22:226–35.
Petersch B, Bogner J, Dieckmann K, et al. Automatic real-time surveillance of eye position and gating for stereotactic radiotherapy of uveal melanoma. Med Phys. 2004;31:3521–7.
Sarici AM, Pazarli H. Gamma-knife-based stereotactic radiosurgery for medium- and large-sized posterior uveal melanoma. Graefes Arch Clin Exp Ophthalmol. 2013;251:285–94.
Wen JC, Oliver SC, Mccannel TA. Ocular complications following I-125 brachytherapy for choroidal melanoma. Eye. 2009;23:1254–68.
Puusaari I, Heikkonen J, Kivelä T. Ocular complications after iodine brachytherapy for large uveal melanomas. Ophthalmology. 2004;111:1768–77.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Jennelle, R.L.S., Berry, J.L., Kim, J.W. (2018). Uveal Melanoma. In: Chang, E., Brown, P., Lo, S., Sahgal, A., Suh, J. (eds) Adult CNS Radiation Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-42878-9_17
Download citation
DOI: https://doi.org/10.1007/978-3-319-42878-9_17
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-42877-2
Online ISBN: 978-3-319-42878-9
eBook Packages: MedicineMedicine (R0)